High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.

Published

Journal Article

Twenty-six patients with breast cancer who had relapsed after previously receiving high-dose chemotherapy and autologous hematopoietic cell support received a second course of high-dose cytoreductive therapy and autologous hematopoietic cell support as salvage therapy. Several different high-dose therapy regimens were employed for the second transplant, including a radiolabeled immunoconjugate. Two patients died of treatment-related complications. The remaining 24 patients relapsed a median of 126 (range 22-635) days after salvage transplant. All have since died. The median survival after salvage transplant was 362 (range 31-931) days. We conclude that second courses of high-dose therapy as salvage treatment are generally well-tolerated but their efficacy is modest. Alternative treatment strategies are needed for these patients.

Full Text

Duke Authors

Cited Authors

  • Bearman, S; Vredenburgh, J; Cagnoni, P; Shpall, E; Nieto, Y; Ross, M; Peters, W; Jones, R

Published Date

  • September 1999

Published In

Volume / Issue

  • 24 / 5

Start / End Page

  • 491 - 495

PubMed ID

  • 10482932

Pubmed Central ID

  • 10482932

Electronic International Standard Serial Number (EISSN)

  • 1476-5365

International Standard Serial Number (ISSN)

  • 0268-3369

Digital Object Identifier (DOI)

  • 10.1038/sj.bmt.1701937

Language

  • eng